A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy ...

so they don’t want to be on concurrent antidepressants.” Spravato is a form of esketamine that patients take as a self-administered nasal spray under the supervision of a healthcare provider.

Esketamine has been shown to affect glutamate signaling in a matter of days, while oral antidepressants can take weeks. Spravato isn’t like the nasal spray you use when you have a cold.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved... The U.S. Food and Drug Administration has ...

Esketamine may be an option for people with major depressive disorder who have already tried at least two antidepressant pills. They may take esketamine on its own or also continue to take an ...

About one-third of adults will not respond to oral antidepressants alone, which has a significant negative impact on the quality of life of those affected. MDD has a high economic burden ...

an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made ...